U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
The FDA approved two first-line Ziihera regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, expanding Jazz Pharmaceuticals’ commercial opportunity through its partnership with Zymeworks. The approval adds a near-term product catalyst for Jazz, but the available financial data still show a business with a -8.3% net margin and $-5.84 diluted EPS.
Jazz Pharmaceuticals said the U.S. Food and Drug Administration approved Ziihera in combination with Tevimbra plus chemotherapy, and Ziihera with chemotherapy, for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. Zymeworks announced the decision on Aug. 25, 2026, identifying Jazz as its partner for the approved asset.
The decision directly connects Jazz, Zymeworks and BeiGene, whose Tevimbra is part of one of the approved regimens. It gives Ziihera a first-line indication in a serious oncology setting and broadens the commercial use cases that Jazz can pursue under its partnership with Zymeworks.
The next read-through will be the launch and uptake of the two regimens, including how oncologists divide use between the Tevimbra-containing option and Ziihera plus chemotherapy. Jazz’s reported FY2025 revenue was $4.3B, up 4.9% YoY, but the company also reported a -8.3% net margin and $-5.84 diluted EPS; the approval therefore creates a product catalyst without, on the supplied figures, establishing its eventual earnings contribution. No dated follow-up event was provided.
The FDA approved two first-line Ziihera regimens for JAZZ in adults with HER2-positive advanced gastroesophageal adenocarcinoma.
The approval creates a concrete commercial expansion for Jazz, but the supplied financial profile does not yet show how much revenue or earnings Ziihera can add: FY2025 revenue was $4.3B, up 4.9% YoY, alongside a -8.3% net margin and $-5.84 diluted EPS. Without a dated forward event or launch metrics, the evidence supports a positive company read but not a conviction trade setup.
The trade weakens if launch uptake is slow or if the approval does not translate into a material contribution against Jazz’s -8.3% net margin and $-5.84 diluted EPS.
CoverageSource: GlobeNewswire · Published here TUE, AUG 25 · 10:23 AM ET · the only report in this recordHow this is decided →
STOCK PHOTO · NOTHING AHEADEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The strongest bull hook is FDA approval of two first-line Ziihera regimens, giving Jazz a broader oncology commercialization opportunity through its partnership with Zymeworks.
The bear case is that Ziihera's launch and sales contributions remain unproven, while Jazz maintains a -8.3% net margin with $-5.84 diluted EPS, leaving the earnings impact uncertain.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →